Evidence map›Paper›PMID 10428902›Full record

ArticleAntimicrobial agents and chemotherapy1999

Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans.

P Mondon, R Petter, G Amalfitano, R Luzzati, E Concia, I Polacheck, K J Kwon-Chung

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 139 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Combating increased antifungal drug resistance inActa biochimica et biophysica Sinica · 2023
    Review
  10. Article
  11. ExploringJournal of fungi (Basel, Switzerland) · 2022
    Article
  12. Review
  13. Article
  14. Clinical utility of antifungal susceptibility testing.JAC-antimicrobial resistance · 2022
    Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

P MondonMolecular Microbiology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, USA.
R Petter
G Amalfitano
R Luzzati
E Concia
I Polacheck
K J Kwon-Chung
National Institute of Allergy and Infectious Diseases · USUniversity of Verona · ITHadassah Medical Center · IL

Funding

Mechanism of Brain Invasion by Cryptococcus neoformansZIAAI000057 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KWON-CHUNG, KYUNG · 2009 to 2017
$2.1M
Mechanism of Brain Invasion by Cryptococcus neoformans Z01AI000057 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI KWON-CHUNG, KYUNG · 1985 to 2008
$1.0M
6 · The paper itself

Abstract

Cryptococcus neoformans isolates that exhibited unusual patterns of resistance to fluconazole and voriconazole were isolated from seven isolates from two different geographical regions: one isolate from an Israeli non-AIDS patient and six serial isolates from an Italian AIDS patient who had suffered six recurrent episodes of cryptococcal meningitis. Each isolate produced cultures with heterogeneous compositions in which most of the cells were susceptible, but cells highly resistant to fluconazole (MICs, >/=64 microg/ml) were recovered at a variable frequency (7 x 10(-3) to 4.6 x 10(-2)). Evidence showed that this type of resistance is innate and is unrelated to drug exposure since the Israeli patient had never been treated with azoles or any other antimycotic agents. Analysis of clonal subpopulations of these two strains showed that they exhibited heterogeneous patterns of resistance. The number of subpopulations which grew on fluconazole or voriconazole agar declined progressively with increasing azole concentration without a sharp cutoff point. For the Italian serial isolates, the number of clonal populations resistant to fluconazole (64 microg/ml) and voriconazole (1 microg/ml) increased steadily, yielding the highest number for the isolate from the last episode. Attempts to purify a sensitive subpopulation failed, but clones highly resistant to fluconazole (100 microg/ml) and moderately resistant to voriconazole (1 microg/ml) always produced a homogeneous population of resistant cells. Upon maintenance on drug-free medium, however, the majority of the homogeneously resistant cells of these subclones lost their resistance and returned to the stable initial heteroresistant phenotype. The pattern of heteroresistance was not affected by the pH or osmolarity of the medium but was influenced by temperature. The resistance appeared to be suppressed at 35 degrees C and was completely abolished at 40 degrees C. Although heterogeneity in azole resistance among subpopulations of single isolates has been reported for Candida species, the transient changes in expression of resistance under different growth conditions reported here have not been observed in fungal pathogens.

Indexed as

Acquired Immunodeficiency SyndromeAdultAmphotericin BAntifungal AgentsCryptococcus neoformansDrug Resistance, MicrobialFluconazoleHumansHydrogen-Ion ConcentrationItraconazoleMaleMeningitis, FungalMicrobial Sensitivity TestsOsmolar ConcentrationPhenotypePyrimidinesAmphotericin BAntifungal AgentsFluconazoleItraconazolePyrimidinesTriazolesVoriconazole

Identifiers

PMID10428902
PMCPMC89380
OpenAlexW2000804360

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.